Status:
COMPLETED
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Lead Sponsor:
University of Cologne
Conditions:
Relapsed NLPHL
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
Eligibility Criteria
Inclusion
- relapsed nodular lymphocyte predominant hodgkin lymphoma
- age 18 - 75
- review of diagnosis by experienced pathologist
- no major organ dysfunction
Exclusion
- classical hodgkin lymphoma
- CD20 antibody treatment within the last 6 months prior enrollment
- chronic or current infectious disease requirering systemic antibiotics
- other past or current malignancy
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01187303
Start Date
May 1 2011
End Date
September 1 2015
Last Update
November 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1st Department of Medicine, Cologne University Hospital
Cologne, Germany